Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
2008
2009
2010
Announcements
Articles
Articles and Publications
Campaign
Case Studies
Charge Capture and Pricing
Coding Integrity
Company
Consulting
Craneware Insights Articles
Education
Home
Journey
News & Events
Opportunities
Other
post
Press Releases
Products
Services
Testimonial
Trade Shows
Uncategorized
Uncategorized
Upcoming Events
Value Cycle
Webinars
White Papers

Is there a new HCPCS code to report when convalescent plasma is administered in the outpatient setting?

Yes.  CMS announced the creation of new HCPCS code, C9507, to report on outpatient claims for convalescent plasma treatment for COVID-19 patients with immunosuppressive challenges.

For your convenience, the long and short code descriptors for HCPCS C9507 are listed below:

Long descriptor: Fresh frozen plasma, high titer COVID-19 convalescent, frozen within 8 hours of collection, each unit

Short descriptor: COVID-19 convalescent plasma

HCPCS code C9507 is retroactively effective to December 28, 2021 to coincide with the date that the FDA expanded its emergency use authorization (EUA) for convalescent plasma to allow its use in the outpatient setting to treat COVID-19 patients with immunosuppressive disease or receiving immunosuppressive treatment. CMS has indicated that payment for C9507 will be $750.50.

CMS MLN Connects dated 12/10/2022:
https://www.cms.gov/outreach-and-educationoutreachffsprovpartprogprovider-partnership-email-archive/2022-02-10-mlnc

CMS site for Hospital Outpatient PPS:
https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS

EUA Letter of Authorization:
https://www.fda.gov/media/141477/download

Skip to toolbar